Liraglutide (Victoza) for type 2 diabetes
- PMID: 20360660
Item in Clipboard
Liraglutide (Victoza) for type 2 diabetes
Med Lett Drugs Ther.
.
Abstract
Liraglutide (Victoza-Novo Nordisk), a glucagon-like peptide-1 (GLP-1) receptor agonist given by subcutaneous injection, has been approved by the FDA for treatment of patients with type 2 diabetes. It can be used alone or in addition to oral antidiabetic drugs such as metformin (Glucophage, and others) or glimepiride (Amaryl, and others). Liraglutide is not recommended for first-line therapy and is not approved for use with insulin.
Similar articles
-
[Liraglutide: a human GLP-1 analogue for the treatment of diabetes mellitus type 2].Med Monatsschr Pharm. 2009 Nov;32(11):402-7. Med Monatsschr Pharm. 2009. PMID: 19947303 Review. German.
-
Clinical pearls for initiating and utilizing liraglutide in patients with type 2 diabetes.J Pharm Pract. 2013 Apr;26(2):144-50. doi: 10.1177/0897190012465985. Epub 2012 Dec 2. J Pharm Pract. 2013. PMID: 23204146 Review.
-
The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.Arch Pharm Res. 2011 Jul;34(7):1041-3. doi: 10.1007/s12272-011-0721-z. Arch Pharm Res. 2011. PMID: 21811909 Review.
-
Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.J Clin Pharm Ther. 2011 Jun;36(3):260-74. doi: 10.1111/j.1365-2710.2010.01180.x. J Clin Pharm Ther. 2011. PMID: 21545609 Review.
-
A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.Clin Ther. 2009 Nov;31(11):2472-88. doi: 10.1016/j.clinthera.2009.11.034. Clin Ther. 2009. PMID: 20109994 Review.
Cited by
-
Non-peptidic glucose-like peptide-1 receptor agonists: aftermath of a serendipitous discovery.Acta Pharmacol Sin. 2010 Sep;31(9):1026-30. doi: 10.1038/aps.2010.107. Epub 2010 Aug 2. Acta Pharmacol Sin. 2010. PMID: 20676118 Free PMC article.
-
Present and future: pharmacologic treatment of obesity.J Obes. 2011;2011:636181. doi: 10.1155/2011/636181. Epub 2011 Feb 8. J Obes. 2011. PMID: 21331293 Free PMC article.
-
Acting on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPER.Front Endocrinol (Lausanne). 2013 Apr 29;4:50. doi: 10.3389/fendo.2013.00050. eCollection 2013. Front Endocrinol (Lausanne). 2013. PMID: 23641235 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
